Jacob Britz focuses his practice on intellectual property litigation, primarily involving pharmaceutical patents under the Hatch-Waxman Act. His experience includes pre-litigation drug launch assessments, Paragraph IV certifications and notice letters, invalidity and non-infringement contentions, fact discovery and claim construction.